Laboratoire francais du fractionnement et des biotechnologies S.A. Indicated for treatment and control of bleeding episodes occurring in adults and adolescents (12 years of age and older) with hemophilia A or B with inhibitors 2 Indicated to treat adult patients with myelodysplastic syndromes 1Ĭoagulation factor VIIa (Recombinant) (Sevenfact) B Indicated to treat patients with non-small-cell lung cancer 2 Indicated for short-term treatment of human immunodeficiency virus type Indicated to treat chronic (long-term) hepatitis delta virus (HDV) infection in adults with compensated liver disease (when the liver is damaged but is still able to work), when the presence of viral RNA (genetic material) has been confirmed by blood tests. Indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) 2 Indicated to treat patients with hereditary angioedema 2īrexucabtagene autoleucel (Tecartus) B,C,G,O Indicated to treat adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C 2 Indicated to treat adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) 2 Indications for new medicines approved by the FDA, the EMA, and/or Health Canada in 2020 Medicine (trade name)*Ītoltivimab, maftivimab, and odesivimab-ebgn (Inmazeb) B,O The following table provides supplementary information on the manufacturer and approved indication(s) for each medicine that received first-time market authorization by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and/or Health Canada in 2020.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |